Point-of-Care Diagnostics Market 2018-2024

  • Product Code:
  • Published Date:
    Mar 2019
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Point-of-Care Diagnostics Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Point-of-care diagnostic test, also referred to as bedside testing or near-patient testing, is a medical diagnostic test conducted outside the laboratory at or near the place where the patient is receiving care. These tests are usually performed by non-laboratory personnel and test results are used for clinical decision making. The complexity and procedures for POC diagnostics may vary from manual methodologies to automated analyzers. These tests are comparatively more expensive than typical laboratory tests but are convenient and cost effective in some clinical settings since these are performed in close proximity to the patient. The best part is that these tests give immediate decisions for clinical management. According to a report released by the Centers for Disease Control and Prevention (CDC), in US alone currently more than 100 million adults are living with diabetes or prediabetes. Cardiovascular diseases (CVD) account for approximately 800,000 deaths in the US. On average, one person dies from CVD every 40 seconds in the US. CVD also causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. There is an increase in life style diseases and developing countries are also suffering from such ailments. It is primarily because of the increasing adoption of Western lifestyle which is expected to fuel the growth of point-of-care diagnostics market in near future.
The point-of-care diagnostics market is booming due to several factors such as the growing patient base for lifestyle diseases globally, growing elderly population, increasing prevalence of infectious disease, technological innovations and increasing adoption of point-of-care diagnostics. Stringent approval processes, unfavorable reimbursement scenarios and product recalls are some of the factors hampering the market growth. The market in emerging countries is expected to grow at a rapid pace during the forecast period because of increasing healthcare awareness towards point-of-care diagnostics, increasing healthcare spending and growing patient pool.
Market Analysis: The “Global Point-of-Care Diagnostics Market” is estimated to witness a CAGR of 7.7% during the forecast period 2018–2024. The market is analyzed based on four segments –products, prescription mode, end-users and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is set to be the leading region for the Point-of-Care Diagnostics market growth followed by Europe, Asia Pacific and the rest of the world.
Product Analysis: The global Point-of-Care Diagnostics market by product is segmented into glucose monitoring kits, infectious diseases testing kits, pregnancy and fertility testing kits, hematology testing kits, cardiometabolic monitoring kits, urinalysis testing kits, coagulation monitoring kits, tumor/cancer markers, cholesterol test strips, drugs-of-abuse testing kits, and others. Glucose monitoring kits occupied the largest share in 2017 due to factors such as an increase in the prevalence of diabetes, change in lifestyle, growing elderly population and increasing demand for disease management.
Prescription Mode Analysis: The global point-of-care diagnostics market by prescription mode is segmented into Prescription-based POC diagnostics and OTC-based POC diagnostics. The latter has occupied a major market share since 2017 and is expected to retain its position during the forecasted period with the introduction of hand-held and portable devices and increased awareness of POC diagnostics.
End-Users Analysis: The global point-of-care diagnostics market by end-users is segmented into hospitals, clinics, home-care and others. Hospitals occupied the maximum market share in 2017 and is expected to be same for the next few years.
Key Players: Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Siemens AG, Danaher Corporation, Qiagen N.V., BioMerieux S.A., Nova Biomedical, Beckton Dickinson and Company, Trinity Biotech plc and other niche players.
Competitive Analysis: Currently, the glucose monitoring kits dominate the global point-of-care diagnostics market. A lot of new players are concentrating on this market to deliver advanced and innovative products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. For instance, in October 2017, Abbott completed the acquisition of Alere for about $5.3 billion. In January 2017, Werfen acquired Accriva Diagnostics, a global leader in in vitro diagnostic (IVD) blood testing at the Point-of-Care (POC). The acquisition included Accriva’s flagship product portfolio spanning coagulation, platelet aggregation, CO-Oximetry and incision devices. Not only this but key players are also launching new products to have an edge in the market. For instance, in January 2018, Abbott Laboratories announced the launch of CE marked Alinity h-series integrated system for hematology testing.
Benefits: The report provides complete details about the usage and adoption rate of point-of-care diagnostics products in various regions. With the help of this report, key stakeholders will find extensive details about the major trends, drivers, investments and vertical players’ initiatives. It will also shed light on government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on the market growth. Additionally, the report gives in-depth information about the key business opportunities to key stakeholders so that they can expand their businesses and forecast the revenue in specific verticals before investing or expanding their businesses in this market.
Key Stakeholders:

Table of Contents
1.1 Industry overview 10
1.2 Total addressable market 10
1.3 Industry Trends 11
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 12
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Advantages of Point-of-care testing 14
3.3 Disadvantages of Point-of-care testing 14
3.4 Segmented Addressable Market (SAM) 14
3.5 Trends of the point-of-Care diagnostics market 15
3.6 Related Markets 16
3.6.1 Molecular diagnostics 16
3.6.2 Infectious disease diagnostics 16
4 Market Outlook 16
4.1 Overview 16
4.2 Funding scenario 17
4.3 Market segmentation 19
4.4 PEST Analysis 19
4.5 Porter 5(Five) Forces 21
5 Market Characteristics 22
5.1 DRO – Global Point-of-care Diagnostics Market Dynamics 22
5.1.1 Drivers 22 Increasing prevalence of infectious disease 22 Growing incidence of life-style disease 23 Technological innovations 23 Increasing adoption of point-of-care diagnostics 24
5.1.2 Opportunities 24 Growth opportunities in emerging markets 24 Increasing awareness towards point-of-care diagnostics in developing countries 25
5.1.3 Restraints 25 Stringent approval process 25 Product recalls 26 Unfavorable reimbursement scenario 26
6 Product: Market Size and Analysis 29
6.1 Overview 29
6.2 Glucose monitoring kits 31
6.3 Infectious disease testing kits 32
6.4 Pregnancy and fertility testing kits 33
6.5 Hematology testing kits 35
6.6 Cardiometabolic monitoring kits 35
6.7 Urinalysis testing kits 37
6.8 Coagulation monitoring kits 38
6.9 Tumour or cancer marker testing kits 39
6.10 Cholesterol testing kits 40
6.11 Drugs of abuse testing kits 40
6.12 Others 41
7 Prescription mode: Market Size and Analysis 42
7.1 Overview 42
7.2 Prescription-based point-of-care diagnostics 44
7.3 Over the counter-based point-of-care diagnostics 45
8 End Users: Market Size and Analysis 46
8.1 Overview 46
8.2 Hospitals 47
8.3 Clinics 47
8.4 Home-care 48
8.5 Others 48
9 Regions: Market Size and Analysis 49
9.1 Overview 49
9.2 North America 50
9.2.1 Overview 50
9.2.2 US 51
9.2.3 Canada 52
9.3 Europe 52
9.3.1 Overview 52
9.3.2 UK 53
9.3.3 Germany 53
9.3.4 France 54
9.3.5 Spain 54
9.4 APAC 54
9.4.1 Overview 54
9.4.2 India 55
9.4.3 China 56
9.5 Rest of the World 56
10 Competitive Landscape 57
10.1 Overview 57
11 Vendor Profiles 61
11.1 Abbott Laboratories 61
11.1.1 Overview 61
11.1.2 Business Unit 64
11.1.3 Geographic Presence 65
11.1.4 Business Focus 66
11.1.5 SWOT Analysis 67
11.1.6 Business Strategy 67
11.2 F.Hoffmann-La Roche Ltd 68
11.2.1 Overview 68
11.2.2 Business Unit 71
11.2.3 Geographic Presence 72
11.2.4 Business Focus 73
11.2.5 SWOT Analysis 73
11.2.6 Business Strategy 74
11.3 Johnson & Johnson 75
11.3.1 Overview 75
11.3.2 Business Units 78
11.3.3 Geographic Revenue 79
11.3.4 Business Focus 80
11.3.5 SWOT Analysis 81
11.3.6 Business Strategies 81
11.4 Danaher Corporation 82
11.4.1 Overview 82
11.4.2 Business Unit 86
11.4.3 Geographic Presence 86
11.4.4 Business Focus 87
11.4.5 SWOT Analysis 88
11.4.6 Business Strategy 88
11.5 Siemens Healthineers Inc. (Siemens AG) 89
11.5.1 Overview 89
11.5.2 Business Units 92
11.5.3 Geographic Presence 94
11.5.4 Business Focus 94
11.5.5 SWOT Analysis 95
11.5.6 Business Strategy 95
12 Companies to Watch For 96
12.1 Trinity Biotech plc 96
12.1.1 Overview 96
12.1.2 Trinity Biotech plc: Recent Developments 97
12.2 Qiagen N.V. 97
12.2.1 Overview 97
12.2.2 Qiagen N.V.: Recent Developments 97
12.3 BioMerieux S.A. 101
12.3.1 Overview 101
12.3.2 BioMerieux S.A.: Recent Developments 102
12.4 OraSure Technologies, Inc. 103
12.4.1 Overview 103
12.4.2 OraSure Technologies, Inc.: Recent Developments 104
12.5 Instrumentation Laboratory (a Werfen company) 104
12.5.1 Overview 104
12.5.2 Instrumentation Laboratory: Recent Developments 105
12.6 Becton Dickinson and Company 106
12.6.1 Overview 106
12.6.2 Becton dickenson and company: Recent Developments 107
12.7 Nova Biomedical 107
12.7.1 Overview 107
12.7.2 Nova Biomedical: Recent Developments 108
13 Annexure 110
13.1 Abbreviations 110

Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
 Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Siemens AG, Danaher Corporation, Qiagen N.V., BioMerieux S.A., Nova Biomedical, Beckton Dickinson and Company, Trinity Biotech plc and other niche players
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports